+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma

Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma

Endocrinologia Japonica 32(6): 811-817

To evaluate the PRL secretory mechanism in patients with PRL-secreting adenoma (PRL-oma), plasma PRL responses to dopamine (DA) were studied in these cases and in normal subjects. Plasma PRL values showed clear decreases during the infusion of DA (5 .mu.g/kg/min for 90 min) in both 6 normal and 7 PRL-oma subjects (% decrease: 43.8 .+-. 3.9% vs. 53.9 .+-. 5.6%; NS) and postinhibitory increases after the termination. However, the postinhibitory increase occurred more promptly and markedly in PRL-oma patients than in normal subjects, i.e. the postinhibitory increase exceeded the basal level 45 min after the normal subjects, i.e., the postinhibitory increase exceeded the basal level 45 min after the termination of DA infusion in PRL-oma patients, whereas the increase in normal subjects did not exceed the basal level even 90 min after the infusion. When domperidone was injected at the termination of DA infusion, the postinhibitory increases were significantly enhanced in either PRL-oma or normal subjects. The maximal increments in plasma PRL in the combination test of DA plus domperidone were significantly larger in PRL-oma patients, but were almost the same in normal controls, compared to the single domperidone test. In contrast, TRH did not modify the postinhibitory rises in 9 PRL-oma patients. These results indicate that the secretory properties and the sensitivities of lactotrophs to decreasing action of DA might be different between PRL-oma patients and normal controls. Further, the postinhibitory rebound phenomenon in PRL-oma patients is possibly determined by an overshoot of PRL storage concomitantly with a decreasing DA action. The PRL secretory properties of lactotrophs and the hypothalamic DA might play important roles in the postinhibitory increases in PRL secretion in patients with PRL-oma.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 005915377

Download citation: RISBibTeXText

PMID: 3938732

DOI: 10.1507/endocrj1954.32.811

Related references

Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma. Acta Endocrinologica 110(4): 445-450, 1985

25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma. Endocrine Metabolic and Immune Disorders Drug Targets 17(3): 219-225, 2017

Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma. Metabolism: Clinical and Experimental 34(9): 874-879, 1985

Restoration of prolactin response to metoclopramide by chronic bromocriptine treatment in patients with prolactin secreting pituitary micro adenoma. IRCS (International Research Communications System) Medical Science Library Compendium 9(4): 375, 1981

Control of phospholipid turnover and prolactin release in a dopamine-sensitive, prolactin-secreting rat pituitary adenoma and in two dopamine-resistant, prolactin-secreting rat pituitary tumors. Journal of Neuroendocrinology 2(6): 833-838, 1990

Role of H2 receptors in controlling prolactin release. Decreased response to cimetidine in patients with prolactin-secreting adenoma and idiopathic hyperprolactinemia. Minerva Ginecologica 36(6): 293-297, 1984

Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. Metabolism: Clinical and Experimental 31(11): 1100-1104, 1982

Dopaminergic regulation of prolactin synthesis in human prolactin secreting adenoma cells in primary culture. Society for Neuroscience Abstracts 12(1): 5, 1986

Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Hormone and Metabolic Research 46(13): 939-942, 2015

Calmodulin content in human prolactin-secreting pituitary adenoma: an inverse relationship to serum prolactin levels. Neuroscience Letters 90(1-2): 224-228, 1988

Prolactin secreting adenoma in man and the role of prolactin in spermatogenesis. Journal of Endocrinological Investigation 3(2): 155-161, 1980

Evaluation of functional periodicity of the pituitary gland by harmonic analysis.--III Circadian prolactin secretion in subjects with prolactin-secreting adenoma. Bollettino Della Societa Italiana di Biologia Sperimentale 59(4): 455-461, 1983

Pulsar analysis of the 24-hour secretion of GH in normal subjects, in acromegalics and in patients with non-secreting and prolactin-secreting pituitary adenoma. Recenti Progressi in Medicina 79(10): 400-406, 1988

Effect of a prolactin and acth secreting tumor on peripheral plasma gonadotropins and prolactin and on hypophyseal stalk plasma lhrh and dopamine in male rats. Journal of Endocrinology 94(Suppl.): 2P, 1982

Release of thyrotropin releasing hormone (TRH) from human prolactin-secreting pituitary adenoma cells. Modulation by dopamine. Comptes Rendus de l'Academie des Sciences. Serie Iii Sciences de la Vie 306(3): 129-134, 1988